Orphenadrine citrate is a prescription muscle relaxant used primarily to relieve pain and stiffness from muscle injuries, strains, and spasms. It has been on the market since the 1950s and remains widely prescribed, often in combination with acetaminophen (paracetamol) or aspirin plus caffeine. What makes orphenadrine unusual among muscle relaxants is the sheer range of pharmacological actions packed into one molecule: it is anticholinergic, blocks certain pain-sensing sodium channels, and acts on receptors in the brain typically associated with anesthetics and neuroprotective drugs. That layered pharmacology explains both its effectiveness and the caution required when using it.
What Orphenadrine Citrate Actually Does in the Body
Most people hear “muscle relaxant” and assume the drug works directly on muscles. Orphenadrine does not. It acts in the central nervous system, altering how the brain and spinal cord process pain signals and muscle tone. Its oldest-known action is anticholinergic: it blocks the neurotransmitter acetylcholine at certain receptor sites. That property is why orphenadrine was originally explored as a treatment for drug-induced parkinsonism, a condition where excess cholinergic activity contributes to tremor and rigidity.
Research over the past few decades has revealed that anticholinergic activity is only part of the story. Orphenadrine also blocks NMDA receptors, a type of glutamate receptor in the brain involved in pain amplification and excitotoxicity. Patch-clamp studies on neurons showed that orphenadrine blocks open NMDA receptor channels in a voltage-dependent manner with fast kinetics.1PubMed. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies Separately, laboratory work on cerebellar neurons found that orphenadrine prevented the collapse in cell membrane potential normally triggered by NMDA activation, confirming it can protect nerve cells from glutamate-driven damage.2PubMed. In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity
On top of those two mechanisms, orphenadrine inhibits voltage-gated sodium channels, specifically the Nav1.7, Nav1.8, and Nav1.9 subtypes that are critical for transmitting pain signals. This blockade occurs at clinically relevant concentrations, meaning the doses people actually take are enough to produce the effect.3PubMed. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine So orphenadrine is doing at least three things at once: dampening cholinergic activity, quieting excitatory glutamate signaling, and reducing pain transmission through sodium channel blockade. That triple action likely explains why it provides noticeable pain relief beyond what a simple muscle relaxant would.
Approved Uses and How Well It Works
The standard indication for orphenadrine citrate is the relief of discomfort associated with acute, painful musculoskeletal conditions. In practice, doctors prescribe it for back pain, neck pain, muscle strains, and the kind of diffuse soreness that follows injury or overuse. Human placebo-controlled studies have shown some support for orphenadrine acting as a mild analgesic on its own in painful conditions tied to muscle spasm.4PubMed. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions
That said, the word “mild” matters. A comparative analysis of seven skeletal muscle relaxants, including orphenadrine, cyclobenzaprine, tizanidine, baclofen, metaxalone, methocarbamol, and diazepam, found no statistically significant differences in functional improvement between any of them or placebo when measured by a standard disability questionnaire.5PubMed. The Relative Efficacy of Seven Skeletal Muscle Relaxants. An Analysis of Data From Randomized Studies The mean improvement scores were remarkably similar across all groups. This is a finding that surprises many patients and even some clinicians. It does not necessarily mean muscle relaxants are useless; short-term symptom relief, particularly with sleep and acute spasm, can still matter to the person in pain. But the evidence for dramatic functional improvement over placebo is thin for the entire drug class, not just orphenadrine.
The Combination With Acetaminophen
Orphenadrine is frequently prescribed alongside acetaminophen (sold under brand names like Norgesic and various generics). The rationale is that the two drugs attack pain through different pathways and together produce more relief than either alone. Animal studies found that the combination significantly improved pain reduction compared to either drug by itself, and the effect lasted longer: more than two hours for the combination versus about 80 minutes for each drug alone.6PubMed. Orphenadrine citrate increases and prolongs the antinociceptive effects of paracetamol in mice Interestingly, orphenadrine could restore acetaminophen’s painkilling effect even when given 90 minutes after acetaminophen had already worn off, suggesting a genuine synergistic interaction rather than just two drugs stacking their individual effects.
In human trials, the orphenadrine-acetaminophen combination produced statistically significant pain relief from baseline starting around the second day of treatment, and was significantly better than placebo by the third day, in patients with neck muscle pain.7PubMed. Effect of a combination of orphenadrine/paracetamol tablets (‘Norgesic’) on myalgia: a double-blind comparison with placebo in general practice Some formulations also add aspirin and caffeine to the mix. While these multi-ingredient products are convenient, they raise practical concerns about acetaminophen dosing: patients who take the combination product and then reach for extra acetaminophen for a headache can inadvertently push themselves toward liver-toxic doses. If you are prescribed an orphenadrine combination product, it is worth checking the label for total acetaminophen content before adding any other over-the-counter pain reliever.
How Long It Stays in Your System
Orphenadrine citrate is usually taken as a 100 mg tablet twice daily, or as an extended-release formulation. After a single dose, blood levels typically peak at around three hours.8Journal of Chromatography B. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) The drug has a fairly long half-life, which is the time it takes for the blood concentration to drop by half. In single-dose studies, the half-life has ranged from roughly 13 to 26 hours depending on the formulation and population studied.9PubMed. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man
There is a clinically important wrinkle here. After repeated dosing, the half-life increases two- to threefold compared to a single dose. That means orphenadrine accumulates in the body over time more than you would expect from the single-dose numbers. If you take it for several days and then stop, it can take considerably longer to clear your system than you might assume. This accumulation partly explains why side effects sometimes seem to creep up after several days of use rather than hitting immediately.
Side Effects at Normal Doses
The most common side effects are exactly what you would predict from an anticholinergic drug: dry mouth, drowsiness, and mild nausea.10European Journal of Gastroenterology & Hepatology. Orphenadrine in treatment of muscle cramps in cirrhotic patients: a randomized study Some people also experience blurred vision, urinary hesitancy, and constipation. These effects are usually manageable at standard doses but can become bothersome for people who are also taking other medications with anticholinergic properties, such as certain antihistamines, antidepressants, or bladder medications. The anticholinergic burden adds up, and the side effects can compound in ways that catch people off guard.
Drowsiness is worth flagging specifically. Many muscle relaxants cause sedation, and orphenadrine is no exception. Combining it with alcohol or other central nervous system depressants intensifies the sedation. Driving or operating machinery on orphenadrine calls for the same caution you would apply after taking a sedating antihistamine.
Drug Interactions Through Liver Enzymes
One of the less-discussed but clinically significant features of orphenadrine is how aggressively it interferes with liver enzymes that metabolize other drugs. In studies using human liver microsomes, orphenadrine strongly decreased the activity of CYP2B6 and CYP2D6 enzymes, reducing their function by as much as 80 to 97 percent. It also partially inhibited CYP1A2, CYP2A6, CYP3A4, CYP2C19, and CYP2C9.11PubMed. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes That is a remarkably broad footprint.
In practical terms, this means orphenadrine can slow the breakdown of many other medications, causing their blood levels to rise unexpectedly. CYP2D6, for example, is the primary enzyme for metabolizing codeine, tramadol, many antidepressants, and some beta-blockers. If orphenadrine is shutting down CYP2D6 activity by 80 to 90 percent, a patient taking one of those medications alongside orphenadrine could experience a significant and potentially dangerous spike in the other drug’s concentration. This interaction is not always flagged prominently in pharmacy software, so it is worth mentioning to your prescriber if you are on multiple medications.
Why Orphenadrine Is Problematic for Older Adults
Geriatric prescribing guidelines in multiple countries flag orphenadrine as a potentially inappropriate medication for older adults. A consensus project developing explicit criteria for Korean older adults included orphenadrine on its list of drugs to avoid, citing its strong anticholinergic properties, poor tolerability in older people due to sedation, and increased risk of fractures from falls.12PubMed Central. Development of a Consensus List of Potentially Imappropriate Medications for Korean Older Adults Similar concerns appear in the American Geriatrics Society’s Beers Criteria and comparable lists worldwide.
The reasoning is straightforward. Anticholinergic drugs in older adults are linked to confusion, cognitive impairment, urinary retention, and constipation, all of which are already more common with aging. The sedation adds fall risk, and falls in older adults frequently lead to hip fractures and hospitalizations. Combined with the long and accumulating half-life described earlier, orphenadrine can build up to troublesome levels in people whose kidney and liver function have declined with age. If you are over 65 and a doctor prescribes orphenadrine, it is reasonable to ask whether a shorter-acting alternative might be safer.
Overdose and Toxicity
Orphenadrine overdose is a medical emergency, though outcomes with modern supportive care are generally survivable. A retrospective poisons-center study examining deliberate self-poisoning cases found that the most common features were drowsiness (59 percent of cases), rapid heart rate (37 percent), and confusion (33 percent). A small number of patients experienced mild low blood pressure, coma requiring intubation, or seizures. No patients developed dangerous ventricular heart rhythm disturbances, and all survived, with three-quarters being medically cleared within 24 hours.13PubMed. Clinical outcomes associated with orphenadrine deliberate self-poisoning: a retrospective poisons centre study
Older case reports painted a more alarming picture. A series of eight suicidal overdose cases from a Rome hospital described all patients arriving in coma with dangerous cardiac arrhythmias, though all eight survived with supportive care including respiratory and cardiovascular assistance.14PubMed. Cardiotoxicity from orphenadrine intoxication in humans The difference between these older reports and the newer poisons-center data likely reflects both better emergency medicine and a broader, more representative sample of overdose severities in the newer study. The takeaway is that while orphenadrine can be dangerous in overdose, particularly regarding the heart and central nervous system depression, fatalities are uncommon with appropriate hospital treatment.
Misuse Potential
Orphenadrine is not a controlled substance and is not typically thought of as a drug of abuse. However, any medication that produces psychoactive effects can be misused at high enough doses. Orphenadrine’s anticholinergic properties can produce euphoria, hallucinations, and a dissociative “high” at supratherapeutic doses, similar to other anticholinergic drugs. Reviews examining the abuse of medications that theoretically lack abuse potential have included skeletal muscle relaxants and anticholinergics as classes where misuse occurs, though it is far less common than misuse of opioids or benzodiazepines.15PubMed. Neuroprotective potential of orphenadrine in focal cerebral ischemia: A neurobehavioral and mechanistic study In some countries, particularly in parts of Africa and the Middle East, orphenadrine misuse has been reported at higher rates than in Western markets. If you notice escalating use beyond prescribed doses, it is worth bringing up with a healthcare provider.
An Unexpected Use in Liver Disease
One of the more interesting off-label applications for orphenadrine is in treating muscle cramps in patients with liver cirrhosis. These cramps are extremely common in cirrhosis, severely impair quality of life, and are notoriously difficult to manage since quinine, once the go-to treatment, was pulled from use for cramps due to safety concerns. A pilot study found that one month of orphenadrine treatment reduced cramp frequency from roughly 12 to 13 episodes per week down to less than one per week, cramp duration dropped from a minute to about six seconds, and pain scores fell from 8 out of 10 to zero.16PubMed Central. Pilot study of orphenadrine as a novel treatment for muscle cramps in patients with liver cirrhosis A separate randomized study confirmed the benefit and noted only minor side effects.17European Journal of Gastroenterology & Hepatology. Orphenadrine in treatment of muscle cramps in cirrhotic patients: a randomized study
These results are striking given how few effective options exist for cirrhosis-related cramps. The finding makes pharmacological sense: the sodium channel blockade and NMDA antagonism could both plausibly reduce the hyperexcitability that drives repetitive muscle cramping. For patients with cirrhosis who are suffering from frequent cramps, this is one of the few areas where orphenadrine’s evidence is genuinely encouraging, though the studies are small and larger trials would strengthen confidence.
Citrate Versus Hydrochloride
Orphenadrine is available as two salt forms: the citrate and the hydrochloride. The citrate salt is by far the more common formulation for oral and injectable use in most markets. The hydrochloride form is encountered less frequently and has historically been used in some European products. The active molecule in both cases is the same orphenadrine base; the salt form affects factors like solubility, tablet stability, and to some extent absorption rate, but the clinical effects at equivalent doses are the same. If you see both listed in a pharmacy reference, the distinction is about formulation chemistry, not about one being stronger or more effective than the other.
Emerging Neuroprotection Research
The discovery that orphenadrine blocks NMDA receptors has sparked interest in whether it could protect the brain during stroke. A recent animal study tested orphenadrine in a rat model of focal cerebral ischemia, essentially mimicking a stroke. Orphenadrine-treated rats showed significantly improved neurological function, muscle strength, and movement ability over the three weeks following the stroke. The drug reduced the volume of dead brain tissue, lowered markers of oxidative damage, and decreased levels of inflammatory molecules in the brain.18PubMed. Neuroprotective potential of orphenadrine in focal cerebral ischemia: A neurobehavioral and mechanistic study Earlier work had shown similar neuroprotective effects against a different type of chemical neurotoxicity, where orphenadrine shielded brain cells from damage caused by mitochondrial poisoning.19PubMed Central. Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo
None of this means orphenadrine is ready for use as a stroke treatment in humans. The history of neuroprotection research is littered with drugs that looked spectacular in rodent models and failed completely in clinical trials. But the findings are consistent across multiple labs and multiple injury models, and orphenadrine has the practical advantage of already being an approved medication with decades of safety data. If a clinical trial were ever designed, the regulatory path would be simpler than for a brand-new compound. For now, this remains firmly in the “promising early-stage science” category, but it highlights how much more is going on pharmacologically with orphenadrine than the phrase “muscle relaxant” suggests.